348 related articles for article (PubMed ID: 15172630)
61. Beyond lowering circulating LDL: apheresis-induced changes of systemic oxidative stress markers by four different techniques.
Kopprasch S; Graessler J; Bornstein SR; Schwarz PE; Tselmin S; Frind A; Poberschin I; Julius U
Atheroscler Suppl; 2009 Dec; 10(5):34-8. PubMed ID: 20129371
[TBL] [Abstract][Full Text] [Related]
62. Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia.
Wang A; Richhariya A; Gandra SR; Calimlim B; Kim L; Quek RG; Nordyke RJ; Toth PP
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27385428
[TBL] [Abstract][Full Text] [Related]
63. LDL-apheresis by dextran sulfate cellulose adsorption columns: two methods.
Falco C; Scarpato N; Nappi G; Postiglione A; Gnasso A; Motti C; Montefusco S; Formisano S
Beitr Infusionsther; 1988; 23():191-4. PubMed ID: 2484777
[No Abstract] [Full Text] [Related]
64. Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol.
Opole IO; Belmont JM; Kumar A; Moriarty PM
Am J Cardiol; 2007 Nov; 100(9):1416-8. PubMed ID: 17950800
[TBL] [Abstract][Full Text] [Related]
65. Extracorporeal LDL-cholesterol elimination in the treatment of severe familial hypercholesterolemia.
Bláha M
Acta Medica (Hradec Kralove); 2003; 46(1):3-7. PubMed ID: 12747532
[TBL] [Abstract][Full Text] [Related]
66. Immunosorptive apheresis of LDL.
Borberg H; Gaczkowski A; Oette K; Stoffel W
Prog Clin Biol Res; 1990; 337():163-7. PubMed ID: 2191310
[No Abstract] [Full Text] [Related]
67. [The extracorporeal elimination of LDL cholesterol by apheresis. The indications and methods].
Olbricht CJ
Dtsch Med Wochenschr; 1991 Apr; 116(16):625-30. PubMed ID: 2015780
[No Abstract] [Full Text] [Related]
68. Optimization of the therapeutic procedure during LDL-apheresis--a computerized model.
Blaha M; Masin V; Stransky P; Blaha V; Cermanova M; Maly J; Belada D
Transfus Apher Sci; 2005 Apr; 32(2):149-56. PubMed ID: 15784449
[TBL] [Abstract][Full Text] [Related]
69. Long-term effect of low-density lipoprotein apheresis in patients with heterozygous familial hypercholesterolemia.
Higashikata T; Mabuchi H
Ther Apher Dial; 2003 Aug; 7(4):402-7. PubMed ID: 12887722
[TBL] [Abstract][Full Text] [Related]
70. Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia.
Otto C; Berster J; Otto B; Parhofer KG
J Clin Apher; 2007; 22(6):301-5. PubMed ID: 17935245
[TBL] [Abstract][Full Text] [Related]
71. Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks.
Stefanutti C; Lanti A; Di Giacomo S; Mareri M; De Lorenzo F; Landolfo A; Isacchi G
Transfus Apher Sci; 2004 Aug; 31(1):3-10. PubMed ID: 15294188
[TBL] [Abstract][Full Text] [Related]
72. [Extracorporeal lipid elimination (LDL-apheresis in the treatment of familial hypercholesterolemia: differential filtration versus dextran sulfate adsorption].
Schwaner I; von Baeyer H; Gräfenhahn H; Schwerdtfeger R; Schwartzkopff W
Biomed Tech (Berl); 1988 Jun; 33(6):130-6. PubMed ID: 2462921
[No Abstract] [Full Text] [Related]
73. Treatment of hyperlipidemia with a modified low density lipoprotein apheresis system with dextran sulfate.
Zhao YH; Zou YG; Sun QJ; Xi D; Xing CY
Ther Apher Dial; 2007 Aug; 11(4):249-54. PubMed ID: 17661829
[TBL] [Abstract][Full Text] [Related]
74. Pattern of red blood cells and platelets cholesterol and fatty acids in homozygous familial hypercholesterolemic patients treated with LDL-apheresis.
Stefanutti C; Lucani G; Vivenzio A; Di Giacomo S; Lucani E; Mazzarella B
Clin Ter; 1998; 149(3):231-3. PubMed ID: 9842108
[TBL] [Abstract][Full Text] [Related]
75. LDL apheresis in Japan.
Makino H; Tamanaha T; Harada-Shiba M
Transfus Apher Sci; 2017 Oct; 56(5):677-681. PubMed ID: 28964708
[TBL] [Abstract][Full Text] [Related]
76. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia.
Blaha M; Cermanova M; Blaha V; Jarolim P; Andrys C; Blazek M; Maly J; Smolej L; Zajic J; Masin V; Zimova R; Rehacek V
Atherosclerosis; 2008 Mar; 197(1):264-70. PubMed ID: 17540382
[TBL] [Abstract][Full Text] [Related]
77. [LDL-Apheresis for the treatment of hyperchylomicronemia-induced pancreatitis].
Sattler AM; Bock K; Schmidt S; Maisch B; Schaefer JR
Z Kardiol; 2003; 92(Suppl 3):III64-7. PubMed ID: 14663605
[TBL] [Abstract][Full Text] [Related]
78. Practical considerations for planning a therapeutic apheresis procedure.
Shelat SG
Am J Med; 2010 Sep; 123(9):777-84. PubMed ID: 20541168
[TBL] [Abstract][Full Text] [Related]
79. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
80. State of the art treatment of the most difficult low density lipoprotein (LDL) cholesterol problems: LDL apheresis.
Whayne TF; Zielke JC; Dickson LG; Winters JL
J Ky Med Assoc; 2002 Dec; 100(12):535-8. PubMed ID: 12522946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
